NASDAQ:ADIL Adial Pharmaceuticals Q1 2026 Earnings Report $2.86 -0.13 (-4.19%) As of 01:17 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Adial Pharmaceuticals EPS ResultsActual EPS-$1.48Consensus EPS -$2.73Beat/MissBeat by +$1.25One Year Ago EPSN/AAdial Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAdial Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/8/2026TimeAfter Market ClosesConference Call DateFriday, May 8, 2026Conference Call Time8:00AM ETUpcoming EarningsAdial Pharmaceuticals' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Adial Pharmaceuticals Earnings HeadlinesADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel RallyJune 11, 2026 | msn.comAdial Pharmaceuticals Acquires Azora Therapeutics to Advance Development of Novel Ulcerative Colitis Treatment AT177June 11, 2026 | quiverquant.comQALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.June 15 at 1:00 AM | Weiss Ratings (Ad)Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million FinancingJune 11, 2026 | globenewswire.comAdial Pharmaceuticals Implements Reverse Stock Split to Regain ComplianceMay 19, 2026 | theglobeandmail.comAdial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business UpdateMay 11, 2026 | globenewswire.comSee More Adial Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email. Email Address About Adial PharmaceuticalsAdial Pharmaceuticals (NASDAQ:ADIL), incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy. The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence. This extended-release formulation aims to improve compliance and reduce relapse rates by maintaining therapeutic drug levels without the need for daily dosing. In addition to AD04, Adial is evaluating next-generation implant platforms and potential adjunctive therapies for substance use disorders, seeking to broaden its pipeline through strategic collaborations and in-house research efforts. Adial conducts clinical research primarily in North America, with previous trials extending to select international sites to gather comprehensive safety and efficacy data supporting future regulatory filings. The company operates through partnerships with academic institutions, contract research organizations and specialized clinical investigators to advance its development programs. Led by an executive team with extensive experience in pharmaceutical development, regulatory affairs and commercialization, Adial Pharmaceuticals continues to focus on addressing global challenges in addiction medicine and preparing for regulatory submissions that could pave the way for market entry.View Adial Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the ShowWhy Oracle's 10% Drop May Be Telling the Wrong Story Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
